1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
ValiRx PLC

ValiRx PLC

LLSE:VAL
0.14
GBX
+0.00
(-3.45%)
248.81MMarket Cap
Jun 09Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.13
0.35
0.32
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-23.42
-12.81
-8.33
-10.28
-2.5
-1.17
-0.33
-0.04
-0.02
-0.03
-0.02
-0.01
-0.01
- -
Free Cash Flow per Basic Share
-19.85
-13.28
-11.84
-9.92
-2.18
-1
-0.24
-0.05
-0.02
-0.02
-0.02
-0.01
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
25
14.67
14.52
3.53
1.13
0.65
0.22
0.08
0.06
0.04
0.03
0.01
- -
- -
Tangible Book Value per Share
10.43
2.03
5.8
-0.71
0.09
-0.02
-0.08
0.03
0.01
0.02
0.01
0.01
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
1
4
7
38
65
77
102
132
414
408
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-2,331.33
-3,584.06
-3,271.22
- -
- -
- -
- -
- -
- -
- -
-23,943.11
-4,302.7
-5,809.21
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-3
-3
-2
-5
-3
-4
-2
-1
-2
-2
-2
-2
-2
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-2,079.99
-3,609.07
-2,564.48
- -
- -
- -
- -
- -
- -
- -
-21,226.05
-3,848.71
-7,115.13
- -
Working Capital
1
- -
2
- -
- -
- -
-1
2
1
1
- -
2
1
1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
3
3
5
2
3
3
2
5
3
4
3
4
2
2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-62.83
-105.47
-58.72
-139.57
-109.27
-136.43
-87.2
-39.73
-35.68
-61.87
-56.06
-50.84
-62.24
- -

Capital Structure

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
374
374
743
Market Capitalization
3
2
2

Working Capital

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
2
1
1
Cash, Cash Equivalents & STI
2
1
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.45%
-8.84%
-38.8%
Free Cash Flow
0.4%
-1.58%
-6.12%
Net Income, GAAP
10.38%
11.54%
16.52%
Sales/Revenue/Turnover
- -
- -
-36.97%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.02
2024
- -
- -
-0.01
2025
- -
- -
-0.01

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Mark Edward Eccleston
Full Time Employees
11
Sector
Health technology
Industry
Pharmaceuticals: major
Address
20 Wenlock Road London GL United Kingdom N1 7GU
IPO Date
Feb 28, 2000
Website
valirx.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
ValiRx plc (VAL.L) is a United Kingdom-based biopharmaceutical company that develops oncology therapeutics, companion diagnostics, and treatments for women's health conditions. The company focuses on advancing novel drug candidates through pre-clinical studies, clinical trials, and partnerships to translate innovative science into clinical assets; its core pipeline includes VAL201, a short peptide that has completed Phase I/II trials for prostate cancer; VAL401, a reformulation of the anti-psychotic drug risperidone that has completed Phase II trials for end-stage non-small cell lung cancer; VAL301, a peptide in pre-clinical development for endometriosis; BC201, a peptide-based combination therapy for severe Covid-19 symptoms; and CLX001, a peptide nanoparticle formulation in pre-clinical trials for cancer cell destruction. ValiRx also operates through its wholly owned subsidiary Inaphaea BioLabs, which provides patient-derived cell models and contract research services for drug testing, particularly in oncology. Incorporated in 2000 and headquartered at Stonebridge House, Chelmsford Road, Hatfield Heath, England CM22 7BD, the company conducts research and experimental development on biotechnology across the United Kingdom with strategic collaborations extending to Canada and academic institutions such as the University of Dundee and The Open University. Recent developments include the August 2025 partnership between Inaphaea BioLabs and VoxCell BioInnovation to co-develop vascularized 3D tumor models for triple negative breast cancer drug screening using CLX001; the establishment of a new subsidiary in August 2025 for prostate cancer assets; a June 2025 GBP16 million out-license agreement for VAL401 with Ambrose plus royalties; a June 2025 evaluation agreement between a subsidiary and Omios Biologics; a September 2025 key patent advancement for the Cytolytix nanoparticle platform; and fundraising efforts in late 2024 totaling GBP1.57 million to support pipeline progression.